From Bortezomib to other Inhibitors of the Proteasome and Beyond
Authors:
- 1 May 2013
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 19 (22) , 4025-4038
Abstract
The cancer drug discovery field has placed much emphasis on the identification of novel and cancer-specific molecular targets. A rich source of such targets for the design of novel anti-tumor agents is the ubiqutin-proteasome system (UP-S), a tightly regulated, highly specific pathway responsible for the vast majority of protein turnover within the cell. Because of its critical role in almost all cell processes that ensure normal cellular function, its inhibition at one point in time was deemed non-specific and therefore not worth further investigation as a molecular drug target. However, today the proteasome is one of the most promising anti-cancer drug targets of the century. The discovery that tumor cells are in fact more sensitive to proteasome inhibitors than normal cells indeed paved the way for the design of its inhibitors. Such efforts have led to bortezomib, the first FDA approved proteasome inhibitor now used as a frontline treatment for newly diagnosed multiple myeloma (MM), relapsed/refractory MM and mantle cell lymphoma. Though successful in improving clinical outcomes for patients with hematological malignancies, relapse often occurs in those who initially responded to bortezomib. Therefore, the acquisition of bortezomib resistance is a major issue with its therapy. Furthermore, some neuro-toxicities have been associated with bortezomib treatment and its efficacy in solid tumors is lacking. These observations have encouraged researchers to pursue the next generation of proteasome inhibitors, which would ideally overcome bortezomib resistance, have reduced toxicities and a broader range of anti-cancer activity. This review summarizes the success and limitations of bortezomib, and describes recent advances in the field, including, and most notably, the most recent FDA approval of carfilzomib in July, 2012, a second generation proteasome inhibitor. Other proteasome inhibitors currently in clinical trials and those that are currently experimental grade will also be discussed.Keywords
This publication has 165 references indexed in Scilit:
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- PAD combination therapy (PS‐341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myelomaBritish Journal of Haematology, 2005
- A phase 2 study of two doses of bortezomib in relapsed or refractory myelomaBritish Journal of Haematology, 2004
- ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up‐regulation and tyrosine‐15 hyperphosphorylation of p34Cdc2Cancer, 2003
- The N-end rule and regulation of apoptosisNature Cell Biology, 2003
- Salinosporamide A: A Highly Cytotoxic Proteasome Inhibitor from a Novel Microbial Source, a Marine Bacterium of the New Genus SalinosporaAngewandte Chemie International Edition, 2003
- Crystal structure of the 20 S proteasome:TMC-95A complex: a non-covalent proteasome inhibitor 1 1Edited by I. A. WilsonJournal of Molecular Biology, 2001
- Regulation of p53 stability by Mdm2Nature, 1997
- Eponemycin, a novel antibiotic, is a highly powerful angiogenesis inhibitorBiochemical and Biophysical Research Communications, 1991
- Pituitary multicatalytic proteinase complex. Specificity of components and aspects of proteolytic activityBiochemistry, 1989